Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide, Docetaxel, and Prednisone in Metastatic Castrate Resistant Prostate Cancer
NCT01468532Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Oct 2011
- Primary completion
- Jul 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pasireotide LAR in prostate cancer (PCa), sponsored by Barbara Ann Karmanos Cancer Institute. Started Oct 2011; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01468532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01468532.